Related Experiment Videos
CK20 gene expression: technical limits for the detection of circulating tumor cells
P Champelovier1, F Mongelard, D Seigneurin
1Laboratoire de Cytologie, Centre Hospitalier Universitaire de Grenoble, France. Pierre.Champelovier@ujf-grenoble.fr
Anticancer Research
|September 2, 1999
Summary
Cytokeratin 20 (CK20) mRNA detection for minimal residual disease in epithelial cancers shows promise but requires caution. CK20 mRNA was found in both cancer patients and healthy individuals, necessitating refined detection methods.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- Minimal residual disease (MRD) detection is crucial for cancer treatment monitoring.
- Cytokeratin 20 (CK20) mRNA has been proposed as a potential biomarker for epithelial cancers.
Purpose of the Study:
- To evaluate the suitability of CK20 mRNA expression as a marker for detecting MRD in epithelial cancers.
- To optimize a sensitive nested RT-PCR assay for detecting circulating tumor cells expressing CK20 mRNA.
Main Methods:
- A nested RT-PCR assay was optimized for high sensitivity.
- CK20 mRNA expression was analyzed in epithelial and leukemic cell lines, bladder tumors, peripheral blood from cancer patients and healthy controls, and bone marrow from healthy donors.
Main Results:
- CK20 mRNA was detected in 72% of epithelial cancer patient blood samples and all tested epithelial tumor cells.
- However, CK20 mRNA was also found in 72% of healthy donor blood samples, all healthy donor bone marrow samples, and some leukemic cell lines.
Conclusions:
- CK20 mRNA expression alone may not be sufficiently specific for detecting epithelial cancers due to its presence in healthy individuals.
- Further research is needed to establish threshold levels or develop quantitative methods to differentiate tumor-specific CK20 expression from background transcription.
- Caution is advised when using CK20 as a sole tumor-specific marker in clinical settings.